Abstract: Disclosed herein is a method of treatment or prevention of public speaking anxiety (PSA), which may in some cases present as a symptom of social anxiety disorder (SAD), including the performance only (SAD-PO) subtype of SAD. The method of treatment includes administering an a7 nAChR agonist such as (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane to the individual at a therapeutically effective dose.

Abstract: The disclosure relates generally to improvements in the treatment of pruritus, atopic dermatitis (AD), and associated symptoms with tradipitant. More particularly, it relates to a method for increasing the likelihood of achieving optimal therapeutic response in the treatment of an AD patient, where the AD patient is one for whom a potential therapy of choice may include the administration of an amount of an NK-1 antagonist, e.g. tradipitant effective to treat the patient's AD.

Abstract: Disclosed herein is a method of treatment of a lower respiratory tract infection caused by, e.g., coronavirus disease (COVID-19), influenza, or other virus, comprising treatment with the NK-1 receptor antagonist, tradipitant.

Abstract: Embodiments of the invention relate generally to the treatment of affective disorders and, more particularly, to the treatment of affective disorders in a patient of Majority Black African ancestry.

Abstract: Tasimelteon improves sleep in individuals experiencing an advance in established bedtime.

Abstract: The invention relates generally to improving sleep, post-sleep performance, or both and, more particularly, to so improving without inducing post-sleep effects that would impair an individual's ability to operate machinery or a motor vehicle.

Abstract: Embodiments of the invention relate generally to the treatment of affective disorders and, more particularly, to the treatment of affective disorders in a patient of Majority Black African ancestry.